122
Participants
Start Date
March 5, 2021
Primary Completion Date
November 1, 2022
Study Completion Date
October 8, 2024
DS-8201a 5.4 mg/kg Q3W
DS-8201a for injection will be administered intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W)
DS-8201a 6.4 mg/kg Q3W
DS-8201a for injection will be administered intravenously (IV) at a dose of 6.4 mg/kg every 3 weeks (Q3W)
Memorial Sloan Kettering Cancer Center (MSKCC), New York
Duke University Medical Center, Durham
Sarah Cannon (Tennessee Oncology - Nashville), Nashville
Norton Cancer Institute Audubon, Louisville
University of Michigan Health System, Ann Arbor
The University of Chicago, Chicago
The University of Texas MD Anderson Cancer Center, Houston
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Flinders Medical Centre (FMC), Bedford Park
Blacktown Hospital, Blacktown
Royal Brisbane & Women's Hospital, Brisbane
Monash Medical Centre, Clayton
Peter MacCallum Cancer Centre, Melbourne
UCL St-Luc, Brussels
UZ Antwerpen, Edegem
Universitair Ziekenhuis Gent, Ghent
Hopital Jean Minjoz, Besançon
Hopital Edouard Herriot, Lyon
ICM-Val d'Aurelle, Montpellier
University Hospital of nantes, Nantes
Centre Antoine Lacassagne, Nice
Hopital St Antoine, Paris
Centre de Lutte Contre le Cancer CLCC - Institut Curie, Saint-Cloud
Chu Toulouse, Toulouse
Asst Grande Ospedale Metropolitano Niguarda, Milan
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Istituto Oncologico Veneto Irccs, Padua
Azienda Ospedaliero Universitaria Pisana, Pisa
Aienda Ospedaliera San Camillo Forlanini, Rome
Azienda ULSS 8 Berica, Vicenza
Aichi Cancer Center Hospital, Aichi
National Cancer Center Hospital East, Chiba
National Hospital Organization Shikoku Cancer Center, Ehime
National Hospital Organization Kyushu Cancer Center, Fukuoka
Hokkaido University Hospital, Hokkaido
Kanagawa Cancer Center, Kanagawa
Kindai University Hospital, Osaka
National Hospital Organization Osaka National Hospital, Osaka
National Cancer Center Hospital, Tokyo
The Cancer Institute Hospital of JFCR, Tokyo
National Cancer Center (NCC), Goyang-si
Seoul National University Bundang Hospital, Gyeonggi-do
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital Yonsei University Health System, Seoul
Hospital Clinico y Provincial de Barcelona, Barcelona
Hospital Universitari Vall dHebron, Barcelona
Clinica Universitaria de Navarra - Madrid, Madrid
Hospital Universitario 12 de Octubre, Madrid
Clinica Universitaria de Navarra, Pamplona
Kaohsiung Medical University Chung-Ho Memorial Hospital KMUH, Kaohsiung City
China Medical University Hospital, Taichung
National Cheng Kung University Hospital, Tainan City
National Taiwan University Hospital, Taipei
Chang Gung Memorial Hospital CGMH - Kaohsiung Branch, Taoyuan District
Chang Gung Memorial Hospital-LinKou, Taoyuan District
Beatson Glasgow, Glasgow
The Royal Marsden Hospital, London
UCLH Trust, London
The Christie, Manchester
The Royal Marsden Hospital, Sutton
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Daiichi Sankyo
INDUSTRY